Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention

Clinical trial NCT04503616 · COMPLETED

Trial details

NCT number: NCT04503616
Sponsor: NYU Langone Health
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Graft-versus-host Disease

Start date: 2020-09-16
Primary completion: 2022-12-14
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.